AI
BLUE

ArchPoint Investors’s bluebird bio BLUE Stock Holding History

ArchPoint Investors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-8
Closed -$18K – 157
2017
Q4 		$18K Buy
+8
New +$16.2K 0.01% 146

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ArchPoint Investors's BLUE Position: Q1 2018 in Review

ArchPoint Investors sold out of bluebird bio (BLUE) in Q1 2018, closing a stake of 8 shares — an estimated $18K sold.

ArchPoint Investors first reported a position in BLUE in Q4 2017 and held it in 1 quarter. The position peaked at $18K in Q4 2017. 303 funds tracked by Wall St. Rank hold BLUE as of Q1 2018.

  • ArchPoint Investors reported no remaining bluebird bio position as of Q1 2018 after selling out during the quarter.
  • ArchPoint Investors sold 8 bluebird bio shares in Q1 2018, an estimated $18K.
  • ArchPoint Investors first reported a position in bluebird bio in Q4 2017 and held it in 1 quarter.
  • ArchPoint Investors's bluebird bio position peaked at $18K in Q4 2017.
  • 303 funds tracked by Wall St. Rank held bluebird bio as of Q1 2018.

Based on ArchPoint Investors's 13F filing for Q1 2018, filed 14 May 2018.